The mitochondria-targeted antioxidant peptide SS-31 ameliorated hypertensive cardiomyopathy in rats, reducing cardiac fibrosis, hypertrophy, and diastolic dysfunction — protecting the heart from high blood pressure damage.
Key findingThe mitochondria-targeted antioxidant peptide SS-31 ameliorated hypertensive cardiomyopathy in rats, reducing cardiac fibrosis, hypertrophy, and diast
What the researchers found
The mitochondria-targeted antioxidant peptide SS-31 ameliorated hypertensive cardiomyopathy in rats, reducing cardiac fibrosis, hypertrophy, and diastolic dysfunction — protecting the heart from high blood pressure damage.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy.
Journal of the American College of Cardiology, 58(1), 73-82
Citation
Dai, Dao-Fu; Chen, Tony; Szeto, Hazel; Nieves-Cintrón, Madeline; Kutyavin, Vassily; Santana, Luis F; Rabinovitch, Peter S. (2011). Mitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathy.. Journal of the American College of Cardiology, 58(1), 73-82. https://doi.org/10.1016/j.jacc.2010.12.044